Delcath Schedules Conference Call to Report 2020 Third Quarter Financial Results

Rhea-AI Summary

Delcath Systems, Inc. (NASDAQ: DCTH) announced a conference call on November 11, 2020, at 8:30 AM ET to discuss its third quarter results for the period ending September 30, 2020. The call can be joined via phone or online streaming. Delcath focuses on liver-directed treatments for cancer, utilizing its investigational product, Melphalan Hydrochloride with the Delcath Hepatic Delivery System. The product is currently undergoing the Phase 3 FOCUS Trial for treating hepatic-dominant ocular melanoma, although it has not yet received FDA approval for the U.S. market.

Positive

• Focus on innovative cancer treatment with Melphalan Hydrochloride.
• Conducting Phase 3 FOCUS Trial for ocular melanoma treatment.

Negative

• Melphalan/HDS has not received FDA approval for the U.S. market.

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced that it will host a conference call on November 11, 2020 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2020.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: November 11, 2020
Time: 8:30 AM Eastern Time
Toll Free: 877-407-8035
International: 201-689-8035

The call will also be available over the Internet and accessible at: https://www.webcaster4.com/Webcast/Page/2475/38241.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the Phase 3 FOCUS Trial which is evaluating the safety and efficacy of Melphalan/HDS to treat patients with hepatic-dominant ocular melanoma, we are also evaluating the potential for Melphalan/HDS to treat other forms of metastatic liver cancers. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

When is the Delcath Systems conference call for Q3 2020 results?

The conference call is scheduled for November 11, 2020, at 8:30 AM ET.

What is the purpose of the upcoming Delcath Systems conference call?

The call will discuss the third quarter results for the period ending September 30, 2020.

What is the status of Delcath's investigational product Melphalan Hydrochloride?

Melphalan Hydrochloride is currently undergoing a Phase 3 trial but has not yet been approved by the FDA.

What trial is Delcath Systems conducting for its cancer treatment?

Delcath is conducting the Phase 3 FOCUS Trial evaluating Melphalan/HDS for hepatic-dominant ocular melanoma.

Is Melphalan Hydrochloride available in the U.S.?

No, Melphalan/HDS has not been approved by the FDA for sale in the U.S.